December 11, 2019Open Access

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with hormone-receptor-positive, HER2-negative advanced breast cancer. (Funded by Novartis; MONALEESA-3 ClinicalTrials.gov number, NCT02422615.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Slamon et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8d9b0d2f7327e70ae46b1 https://doi.org/https://doi.org/10.1056/nejmoa1911149

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer2019 · 1,021 citations
2Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-32018 · 1,113 citations
3Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint2011 · 20 citations
4PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro2009 · 1,407 citations
5Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment2006 · 1,026 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo